Possible adverse events*
| Event . | Ruxolitinib (n = 22), n (%) . | Ruxolitinib + additional therapy (n = 30), n (%) . | ||
|---|---|---|---|---|
| Any grade . | Grade ≥3 . | Any grade . | Grade ≥3 . | |
| Hematologic AEs | ||||
| Anemia | 7 (31.8) | 4 (18.2) | 13 (43.3) | 6 (20.0) |
| Thrombocytopenia | 5 (22.7) | 2 (9.1) | 15 (50.0) | 8 (26.7) |
| Neutrocytopenia | 4 (18.2) | 0 | 22 (73.3) | 10 (33.3) |
| Myelosuppression | 0 | 0 | 22 (73.3) | 11 (36.7) |
| Nonhematologic abnormalities | ||||
| Constipation | 10 (45.5) | 0 | 9 (30.0) | 0 |
| Pancreatic damage | 8 (36.4) | 1 (4.5) | 10 (33.3) | 6 (20.0) |
| Rash | 4 (18.2) | 0 | 7 (23.3) | 0 |
| Diarrhea | 3 (13.6) | 0 | 9 (30.0) | 0 |
| Liver damage | 3 (13.6) | 0 | 14 (46.7) | 5 (16.7) |
| Sweating | 2 (9.1) | 0 | 16 (53.3) | 0 |
| Gastritis | 1 (4.5) | 0 | 0 | 0 |
| Secondary infection | 0 | 0 | 17 (56.7) | 7 (23.3) |
| Heart damage | 0 | 0 | 6 (20.0) | 0 |
| Kidney damage | 0 | 0 | 4 (13.3) | 0 |
| Gastrointestinal hemorrhage | 0 | 0 | 5 (16.7) | 3 (10.0) |
| Event . | Ruxolitinib (n = 22), n (%) . | Ruxolitinib + additional therapy (n = 30), n (%) . | ||
|---|---|---|---|---|
| Any grade . | Grade ≥3 . | Any grade . | Grade ≥3 . | |
| Hematologic AEs | ||||
| Anemia | 7 (31.8) | 4 (18.2) | 13 (43.3) | 6 (20.0) |
| Thrombocytopenia | 5 (22.7) | 2 (9.1) | 15 (50.0) | 8 (26.7) |
| Neutrocytopenia | 4 (18.2) | 0 | 22 (73.3) | 10 (33.3) |
| Myelosuppression | 0 | 0 | 22 (73.3) | 11 (36.7) |
| Nonhematologic abnormalities | ||||
| Constipation | 10 (45.5) | 0 | 9 (30.0) | 0 |
| Pancreatic damage | 8 (36.4) | 1 (4.5) | 10 (33.3) | 6 (20.0) |
| Rash | 4 (18.2) | 0 | 7 (23.3) | 0 |
| Diarrhea | 3 (13.6) | 0 | 9 (30.0) | 0 |
| Liver damage | 3 (13.6) | 0 | 14 (46.7) | 5 (16.7) |
| Sweating | 2 (9.1) | 0 | 16 (53.3) | 0 |
| Gastritis | 1 (4.5) | 0 | 0 | 0 |
| Secondary infection | 0 | 0 | 17 (56.7) | 7 (23.3) |
| Heart damage | 0 | 0 | 6 (20.0) | 0 |
| Kidney damage | 0 | 0 | 4 (13.3) | 0 |
| Gastrointestinal hemorrhage | 0 | 0 | 5 (16.7) | 3 (10.0) |
Some patients had more than 1 AE.
Since HLH is characterized by systemic tissue injury, including cytopenia, liver damage, and other organ involvement, some of the AEs may be attributable to HLH activation or coexisting conditions of disease and drug.